JP2021040627A5 - - Google Patents

Download PDF

Info

Publication number
JP2021040627A5
JP2021040627A5 JP2020163153A JP2020163153A JP2021040627A5 JP 2021040627 A5 JP2021040627 A5 JP 2021040627A5 JP 2020163153 A JP2020163153 A JP 2020163153A JP 2020163153 A JP2020163153 A JP 2020163153A JP 2021040627 A5 JP2021040627 A5 JP 2021040627A5
Authority
JP
Japan
Prior art keywords
peptide
cell
cancer
tcr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020163153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021040627A (ja
Filing date
Publication date
Priority claimed from GBGB1602918.3A external-priority patent/GB201602918D0/en
Application filed filed Critical
Publication of JP2021040627A publication Critical patent/JP2021040627A/ja
Publication of JP2021040627A5 publication Critical patent/JP2021040627A5/ja
Pending legal-status Critical Current

Links

JP2020163153A 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ Pending JP2021040627A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662297495P 2016-02-19 2016-02-19
GBGB1602918.3A GB201602918D0 (en) 2016-02-19 2016-02-19 Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB1602918.3 2016-02-19
US62/297,495 2016-02-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018540851A Division JP2019513005A (ja) 2016-02-19 2017-02-17 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Publications (2)

Publication Number Publication Date
JP2021040627A JP2021040627A (ja) 2021-03-18
JP2021040627A5 true JP2021040627A5 (enExample) 2021-05-27

Family

ID=58057145

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020163153A Pending JP2021040627A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020163154A Pending JP2021040628A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020163155A Pending JP2021045124A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020163156A Pending JP2021035361A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020163154A Pending JP2021040628A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020163155A Pending JP2021045124A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020163156A Pending JP2021035361A (ja) 2016-02-19 2020-09-29 Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Country Status (8)

Country Link
US (5) US10702592B2 (enExample)
JP (4) JP2021040627A (enExample)
CN (1) CN114028549A (enExample)
CL (4) CL2018002096A1 (enExample)
CO (1) CO2018008239A2 (enExample)
MA (1) MA55153A (enExample)
PH (1) PH12018501639A1 (enExample)
ZA (1) ZA201805512B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210328930A1 (en) * 2020-01-28 2021-10-21 Intel Corporation Predictive queue depth

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5907800A (en) * 1999-06-30 2001-01-31 Millennium Pharmaceuticals, Inc. Membrane-associated and secreted proteins and uses thereof
US20050164202A1 (en) * 2000-02-03 2005-07-28 Emtage Peter C.R. Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7049096B2 (en) * 2001-04-11 2006-05-23 Bristol-Meyers Squibb Company Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
JP2004229507A (ja) 2003-01-28 2004-08-19 Japan Science & Technology Agency 転写活性化因子
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
WO2010024289A1 (ja) * 2008-08-27 2010-03-04 シスメックス株式会社 Il-17産生ヘルパーt細胞検出用マーカー及びil-17産生ヘルパーt細胞の検出方法
US8877889B2 (en) * 2009-09-02 2014-11-04 Industry-Academic Cooperation Foundation, Chosun University Tumor cell-killing peptides
US9410965B2 (en) 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US20150118244A1 (en) * 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP3511425A1 (en) * 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
ES2452485B1 (es) * 2012-07-13 2015-03-09 Univ Valladolid Mutantes de apoacuorina y metodos para su uso
PT3126381T (pt) 2014-04-01 2019-04-18 Ganymed Pharmaceuticals Ag Imunorrecetores e epítopos de células t específicos da claudina-6
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers

Similar Documents

Publication Publication Date Title
JP2019513005A5 (enExample)
JP2020198875A5 (enExample)
JP2021101700A5 (enExample)
JP2020182458A5 (enExample)
JP2019516663A5 (enExample)
JP2020506690A5 (enExample)
JP2019536426A5 (enExample)
JP2024099580A5 (enExample)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
HRP20230512T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2020516681A5 (enExample)
JP2018529320A5 (enExample)
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
JP2019515653A5 (enExample)
JP2019502360A5 (enExample)
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
JP2011520436A5 (enExample)
JP2010527919A5 (enExample)
JP2019520038A5 (enExample)
FI3273986T3 (fi) Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
JP2020516313A5 (enExample)
JP2020191873A5 (enExample)
JP2020191868A5 (enExample)